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The plant alkaloids castanospermine, dihydroxymethyldihydroxypyrrolidine and deoxynojirimycin have recently been 
shown to have potential anti-HIV activity [(1987) Proc. Natl. Acad. Sci. USA 84,8120-8124; (1987) Nature 330, 7477; 
(1987) Lancet i, 10251026]. They are thought to act by inhibiting a-glucosidase I, an enzyme involved in the processing 
of N-linked oligosaccharides on glycoproteins. We report here the relative efficacy of a spectrum of amino-sugar deriva- 
tives as inhibition of HIV cytopathicity. Several a-glucosidase inhibitors and a-fucosidase inhibitors were found to be 
active at concentrations which were non-cytotoxic. 
AIDS; HIV; Glycosidase inhibitor; Amino-sugar; Glycosylation 
1. INTRODUCTION 
Polyhydroxylated octahydroindolizines, piper- 
idine and pyrrolidine alkaloids extracted from 
plants and microorganisms have been found to 
have a number of biological activities, which in 
most cases can probably be ascribed to their acting 
as glycosidase inhibitors. Many of these alkaloids 
can be considered as analogues of monosac- 
charides in which the ring oxygen is replaced by 
nitrogen. Recent reviews [4,5] have dealt with 
historical and general aspects of these compounds 
and currently there are.about 13 natural alkaloidal 
glycosidase inhibitors reported [5]. They are being 
used to study the mechanisms of oligosaccharide 
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processing and may also be of potential clinical 
value as anti-neoplastic agents [6-g]. Recent 
studies have suggested that those alkaloids which 
inhibit cu-glucosidase I may have anti-HIV activity 
[l-3]. In order to confirm and extend these earlier 
studies we have isolated or synthesized 47 amino- 
sugar derivatives and screened them for potential 
anti-HIV activity. To discriminate between specific 
anti-HIV activity and cytotoxicity we have assessed 
in parallel their effects on HIV infected and non- 
infected T lymphocytes. 
2. MATERIALS AND METHODS 
The T-cell line (Karpas 45) was established from a child with 
acute lymphoblastic Ieukaemia. HIV-l and HIV-2 were both 
isolated in Cambridge, HIV-l from a British patient with AIDS 
and HIV-2 from a West African patient with AIDS. Cell-free 
suspensions of HIV were prepared from infected cultures as 
reported elsewhere [lo]. The concentration of infectious par- 
ticles (TCID, tissue culture infectious dose) was estimated using 
an end-point titration where the number of infectious HIV par- 
ticles in each preparation was determined by the highest dilution 
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which contained infectious HIV, as detected by syncytial forma- 
tion, cytotoxicity and HIV antigen synthesis after 10 days of 
culture with 104 T-45 cells. The efficacy of the compounds used 
in this study was assessed as reported elsewhere [lo]. 
Stock solutions of all compounds were prepared by dissolving 
each compound at a concentration of 1 mg/ml in growth 
medium. These solutions were filtered and sterilised (0.22 firn). 
Initially, each compound was tested at concentrations of 
0.1 mg/ml and 0.5 mg/ml. If a given compound showed inhibi- 
tion of HIV replication without cytotoxicity the assay was 
Table 1 
Cytotoxicity and anti-HIV activity 
Compound Abbreviation Ox no. Compound Cytotoxic Anti-HIV activity 
dosage activity 
(mgiml) (vo cell death) (% CPE reduction) 
Castanospermine 
L- 1,6-Diepicastanospermine 
L-6-Epicastanospermine 
Deoxynojirimycin 
N-Methyl-DNJ 
N-Ethyl-DNJ 
N-(n-Butyl)-DNJ 
2,5-Dideoxy-2,5-imino-D-mannitol 
N-Methyl-DMDP 
1,4-Dideoxy-1,4-imino-D-arabinitol 
N-Methyl-DAB 
1,4-Dideoxy-1,4-imino-L-arabinitol 
N-Methyl-LAB 
1,4-Dideoxy-1 ,Cimino-D-glucitol 
N-Benzyl-l,Cdideoxy-l,Cimino-D-glucitol 
1 ,CDideoxy-l,Cimino-D-mannitol 
N-Methyl-DIM 
D-Mannonic-1,4-lactam 
1,4-Dideoxy-1,4-imino-D-tallitol 
N-Benzyl-1 ,Cdideoxy-1,4-imino-D-tallitol 
D-Deoxymannojirimycin 
N-Methyl-DMJ 
L-Deoxymannojirimycin 
N-Methyl-L-DMJ 
L-Mannonic-1,5-lactam 
Fagomine 
2-Acetamido-1,5-imino-1,2,5-trideoxy-D-glucitol 
2-Acetamido-l,5-imino-l,2,5-trideoxy-D-galactitol 
L-Fuconic-1,Wactam 
l,S-Dideoxy-1,5-imino-L-fucitol 
N-Methyl-FT 
N-Acetyl-FT 
A+Carboxymethyl-1-pentyl) 
1,4-Dideoxy-1 ,Cimino-D-ribitol 
N-Benzyl-DRib 
N-Methyl-DRib 
1 ,CDideoxy-1 ,Cimino-L-ribitol 
N-Benzyl-LRib 
1 ,CDideoxy-1,4-imino-D-galactitol 
D-Galactonic-1 ,blactam 
1 ,CDideoxy-1 ,Cimino-D-allitol 
N-Benzyl-DIA 
2S,3R,4R,5R-3,4,5-TrihydroxypipecoIic acid 
2S,3R,4R-3,4-Dihydroxypipecolic a id 
2S,3R,4R-3,4-Dihydroxyproline 
Dextran sulfate 
Cast 
LDCast 
LECast 
DNJ 
MeDNJ 
EtDNJ 
BuDNJ 
DMDP 
MeDMDP 
DAB 
MeDAB 
LAB 
MeLAB 
DIG 
BzDIG 
DIM 
MeDIM 
DIT 
BzDIT 
DMJ 
MeDMJ 
LDMJ 
MeLDMJ 
FAG 
AGlu 
AGal 
FT 
MeFT 
AcFT 
LFT 
DRib 
BzDRib 
MeDRib 
LRib 
BzLRib 
DIA 
BzDIA 
Dex 
16 
63 
62 
55 
36 
56 
57 
17 
35 
7 
33 
38 
34 
11 
51 
32 
31 
42 
12 
53 
5 
37 
61 
60 
59 
6 
4 
3 
2 
1 
45 
46 
47 
15 
39 
48 
14 
40 
58 
41 
13 
52 
8 
9 
10 
0.1 , 0.4 0, 40 75, 60 
0.1 , 0.5 0, 0 0, 50 
0.1 , 0.5 0, 0 0, 0 
0.5 0 50 
0.1 , 0.5 0,40 100, 40 
0.1 , 0.5 0, 25 100, 75 
0.1 , 0.5 0, 0 100,100 
0.32 35 25 
0.1 0 25 
0.17 0 25 
0.3 0 0 
0.1 , 0.5 0, 0 50, loo 
0.1 0 25 
0.16 0 0 
0.1 0 0 
0.3 -0 10 
0.3 0 10 
0.3 0 0 
0.16 0 25 
0.1 0 0 
0.06 25 0 
0.3 0 25 
0.1 , 0.5 0, 0 0, 0 
0.1 (0.5 0, 0 0, 0 
0.1 , 0.5 0, 0 0, 0 
0.18 25 0 
0.19 25 0 
0.19 0 0 
0.10 25 50 
0.15 0 0 
0.1 0 25 
0.3 0 0 
0.10, 0.25 0, 0 75, 90 
0.13 0 50 
0.1 0 0 
0.1 0 25 
0.13 0 25 
0.1 0 25 
0.1 , 0.5 0, 0 0, 0 
0.3 0 0 
0.16 0 0 
0.1 0 0 
0.16 25 0 
0.18 25 0 
0.15 0 0 
0.01, 1.0 0, 0 25, 60 
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repeated with greater dilutions or, if it showed partial inhibi- 
tion, with higher concentrations. 
0x16 was isolated from Castanospermum australe [II]; 
0x13, 0x15, 0x39, 0x52, were synthesized from D-gulono- 
lactone 1121; 0x59 was synthesized from D-gulonolactone [13]; 
0x62 and 0x63 were synthesized from D-gulonolactone 
[14-161; 0x55 was either isolated [17], purchased from Sigma or 
synthesized from D-glucose (181; 0x36, 0x56 and 0x57 were 
synthesized from deoxynojirimycin [19]; 0x17 was either 
isolated [I71 or also synthesized from D-glucose [20]; 0x35 was 
synthesized from 2,5-dideoxy-2,5-imino-D-mannitol [19]; 0x7 
and 0x38 were synthesized from D-xylose 1211; 0x33 and 0x34 
were synthesized from 1,4-dideoxy-1,4-imino-D-arabinitol [19]; 
0x11 and 0x51 were synthesized from D-galactonolactone [12]; 
0x3 1 was synthesized from 1 ,Cdideoxy-1 ,Cimino-D-mannitol 
1191; 0x12, 0x14, 0x53 and 0x40 [25], 0x32 [23], 0x42 [24] 
and 0x38 119) were all synthesized from D-mannose; 0x37 was 
synthesized from D-deoxymannojirimycin 1191; 0x61 was syn- 
thesized from L-deoxymannojirimycin (19); 0x1 [31], 0x2 [26], 
0x3 [27], 0x4, 0x5, 0x6 and 0x8 [18], 0x9 and 0x10 [28], 
0x15 [18] and 0x41 and 0x58 (241 were all synthesized from 
glucose; 0x45 and 0x47 were synthesized from 
1,5-dideoxy-1,5-imino-L-fucitol [19]; and 0x46 was prepared 
by peracetylation of 1,5-imino-L-fucitol followed by selective 
deacylation [24]. 
3. RESULTS 
Table 1 and fig.1 list the polyhydroxylated 
piperidines, pyrrolidines, and octahydroindolizines 
and others which were tested in this study and the 
effect of these compounds on the cytopathic effect 
(CPE) and their cytotoxicity. The data in table 1 
confirmed the inhibition of CPE by the (Y- 
glucosidase I inhibitor castanospermine (0x16) as 
reported previously [l-3]. In contrast, neither 
L-6-epicastanospermine (0x62) nor L-l ,6-epicasta- 
nospermine (0x63) was inhibitory. Deoxynojiri- 
mycin (Ox%), previously reported to be inhibitory 
[2,3], was found to have only a marginal effect, 
however, the activity was greatly increased by N- 
alkylation; thus the N-methyl (0x36), N-ethyl 
(0x56), and N-butyl (0x57) derivatives were all 
potent inhibitors of CPE at concentrations which 
were not cytotoxic. The azafructose analogue 
(0x17), a hydroxylated pyrrolidine, was found 
to have a weak inhibitory effect. However, N- 
methylation of 0x17 to give 0x35 did not change 
the inhibitory properties of the compound in con- 
trast to the increase in efficacy found after N- 
alkylation of deoxynojirimycin. Both enantiomers 
of 1 ,Cdideoxy-1 ,Cimino-arabinitol (0x7, 0x38) 
were previously shown to be glucosidase inhibitors 
[29,30], although each enantiomer had a different 
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range of glucosidase inhibitor specificity [21]. The 
D-enantiomer (0x7) had very little effect on HIV 
replication, whereas the L-enantiomer (0x38) had 
significant inhibitory properties. For both enan- 
tiomers, N-methylation (0x33, 0x34) reduced the 
anti-HIV activity with total loss of activity of 0x33 
and only marginal inhibition with 0x34. Neither 
the azafuranose analogue of glucose (0x11) nor the 
N-benzyl derivative (0x51) was found to have an 
effect on CPE. Similarly, no inhibition activity was 
observed for fagomine (0x6), the 2-deoxyglucose 
analogue. 
In contrast to the effect of inhibitors of (Y- 
glucosidase I, such as castanospermine, inhibitors 
of processing mannosidases uch as deomanno- 
jirimycin were reported to have no effect on HIV 
replication [2]. Thus the mannosidase inhibitor 
(0x32), the N-methyl derivative (0x31) and the 
corresponding lactam (0x42) all had no effect on 
CPE [54]. However, weak inhibition by the man- 
nosidase inhibitor (0x12) was observed although 
the N-benzyl derivative (0x53) had no effect. 
Deoxymannojirimycin (0x5) was confirmed to 
have only very weak activity as reported elsewhere 
[2], but the corresponding N-methyl derivative 
(0x37) was found to have significant inhibitory ac- 
tivity. Neither of the enantiomers of deoxymanno- 
jirimycin (0x60 and 61) nor the corresponding lac- 
tam (0x59) had any inhibitory effect. 
The effects of a number of other known 
glycosidase inhibitors were also studied. Neither 
the aza analogue of N-acetylglucosamine (0x4) nor 
N-acetylgalactosamine (0x3), which are specific 
hexosaminidase inhibitors [30], had any effect on 
the CPE. The fuconolactam (0x2), which is a weak 
L-fucosidase inhibitor [26], had a significant ef- 
fect, although the powerful fucosidase inhibitor 
0x1 [31] had no effect. However the N-methyl 
(0x45) and N-acetyl (0x46) derivatives of 0x1 
showed weak inhibition. Surprisingly the N-pentyl- 
carboxymethyl derivative (0x47) showed potent in- 
hibition of CPE. The D-ribose derivative (0x15) 
and the enantiomeric L-ribose isomer (0x14) both 
had modest inhibitory effects as did their alkylated 
derivatives (0x48, 0x39, and 0x40). No effects 
were observed with the iminohexitol derivatives 
(0x58, 0x41, 0x13, 0x52) nor the hydroxylated 
amino acids (0x8, 0x9, 0x10). 
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(16) (62)R’.H;ff=OH ISSlRrH 06IR=CH, (17)R.H (7lR=H 136)R =H 
(63)R’.OH;R’.H (56)R=CH,Cn, 571R.CH$HzCH,CH, 05) R=CH, (33) R = CY OLBR.Cy 
(11) R.H SWAINSONINE 
151) R=P~cH, 
l60)R.H (59) 
I61)R=CH, 
OH 
(321 R=H IL21 fl2, RtH (SlRsH 
01) R=CH, (53) R .PhCn, (37lR.04, 
(6) (II (3) (21 
lllR=H(L5lR=CH, 
~COR=CH,CO 147)R.MeOICICH,l, 
(1S)R.H OP)R=PhCH, 
V.(IIR.CH, 
(UlR=H 
(401 R = PhCHl 
HO.... 
(13IR=H (OR.OH (10) 
lS2lR=PhO(, l9)R.H 
Fig. 1. Structural formula of the compounds tested for anti-HIV activity. Table 1 lists the corresponding chemical names and abbrevia- 
tions. The numbers in parenthesis refer to their Ox registry number and are drawn in the same order as they are discussed in the text. 
See section 2 for references on their synthesis. 
4. DISCUSSION 
The data reported here confirm that anti-HIV 
activity is exhibited by a number of amino-sugar 
derivatives some of which are known to interfere 
with oligosaccharide biosynthesis. For example, 
significant activity (inhibition of CPE) was found 
for the compounds (0x16, 36,38,47, 56, 57) while 
compounds 38 and 47 had a lower activity. Of this 
group (0x16, 0x36, 0x57) are known to be in- 
hibitors of cy-glucosidase I [32,33], however, 0x47 
is a potent inhibitor of a-L-fucosidase (un- 
published). 0x38 is known to be an cu-glucosidase 
inhibitor, but has yet to be tested for activity 
against cY-glucosidase I [29,35]. Weak to marginal 
inhibition was found for the compounds 0x62,63, 
16, 55, 17, 34, 2, 45, 48, 14, 40. Of this group 
(0x55, 0x17) are known to be a-glucosidase I in- 
hibitors [32-34,361, (0x7) is an a-glucosidase in- 
hibitor [35] not tested against a-glucosidase 1) and 
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(0x2, 0x45) are known to be fucosidase inhibitors 
[33]. No activity was found for the compounds 
(0x6,0x32) although these compounds are known 
to have a-glycosidase activity [29,35]. The data 
also show that in some cases N-alkylation results in 
a more active compound (55 + 36) while for other 
compounds (7 4 33) there is complete loss of ac- 
tivity. 
From the data reported above, the optimal struc- 
tural requirement for suppression of HIV cyto- 
pathicity is not obvious. However, these observa- 
tions add support to the idea that amino-sugar 
derivatives may be of use in limiting the spread of 
HIV infections. This possibility is explored ex- 
perimentally in a parallel publication [lo]. 
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